Clinical Trials

Current Studies

A5401: ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies

A master protocol to evaluate the safety and efficacy of investigational agents for the treatment of symptomatic non-hospitalized adults with COVID-19. It begins with a phase II evaluation, followed by a transition into a larger phase III evaluation for promising agents.

English A5001 Information

Spanish A5001 Information

Mosaico

The Mosaico clinical trial is designed to test whether an HIV vaccine will work in preventing HIV infection in healthy individuals.

The goal of this study is to evaluate the immune responses of 2 HIV vaccines in men and transgender individuals who have sex with men.

Interested in participating?

Please email D’Jamel Young.

Online Screener

Completed Studies

The Ponce CRS has successfully completed recruitment in a number of treatment and prevention studies related to HIV, TB, and COVID. See below for some of these studies.

Please note - the following studies are no longer enrolling participants

ACTG studies

The Ponce CRS has completed numerous NIH-funded AIDS Clinical Trials Group (ACTG) studies, with more than 500 participants.

HPTN 083

A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men.

Moderna’s mRNA-1273 vaccine, The COVE Study™

The mRNA-1273 vaccine was developed to prevent COVID-19. The purpose of this study was to test Moderna’s vaccine candidate to see if it can prevent illness if people are exposed to the SARS-CoV-2 virus in their everyday lives.

Ponce Clinical Research Site HIV/AIDS Clinical Trials Unit section navigation